Astellas Pharma and CytomX Therapeutics first partnered up in March 2020. For $80 million upfront, the Japanese pharma gained ...

AbbVie Inc. (NYSE:ABBV) is included among the 13 Undervalued Dividend Aristocrats to Buy Now. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that engages in the research and ...

SCYNEXIS, Inc. (NASDAQ:SCYX) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On February 26, 2026, SCYNEXIS, ...

Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...

Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...

Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder ...

Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.

A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01. This is an ASCO Meeting Abstract from the 2025 ...

ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic for long-lasting enhancement of mucociliary clearance Results showed excellent consistency between ...